Syndax Pharmaceuticals Current Ratio 2015-2021 | SNDX

Syndax Pharmaceuticals current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Syndax Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.26B $0.02B 10.81
2021-03-31 $0.28B $0.03B 11.35
2020-12-31 $0.30B $0.02B 15.84
2020-09-30 $0.18B $0.02B 11.71
2020-06-30 $0.19B $0.01B 15.39
2020-03-31 $0.10B $0.02B 5.55
2019-12-31 $0.06B $0.02B 3.39
2019-09-30 $0.08B $0.02B 4.09
2019-06-30 $0.09B $0.02B 4.90
2019-03-31 $0.10B $0.02B 6.24
2018-12-31 $0.08B $0.02B 5.18
2018-09-30 $0.10B $0.02B 5.63
2018-06-30 $0.11B $0.02B 5.43
2018-03-31 $0.12B $0.02B 7.06
2017-12-31 $0.13B $0.02B 8.45
2017-09-30 $0.12B $0.01B 8.73
2017-06-30 $0.13B $0.01B 11.66
2017-03-31 $0.10B $0.01B 8.83
2016-12-31 $0.11B $0.01B 10.47
2016-09-30 $0.12B $0.01B 12.82
2016-06-30 $0.13B $0.01B 19.44
2016-03-31 $0.14B $0.01B 19.30
2015-12-31 $0.09B $0.01B 18.16
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.01B $0.01B 1.20
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.915B $0.002B
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71